Kiniksa Q2 ARCALYST revenue $54.5M; raises FY2023 guidance to $220-230M

Kiniksa Pharmaceuticals International, plc

2023-Q2 EPS reported $0.04 revenue$119,818,000

Q2 total revenue $71.5M (vs $27.0M YoY), ARCALYST net product revenue $54.5M (vs $27.0M YoY).
Net income $15.0M vs net loss $20.0M YoY; includes $16.2M tax benefit from valuation allowance release.
2023 ARCALYST revenue guidance raised to $220-230M from $200-215M; cash runway extended into at least 2027.
Over 1,250 prescribers have written ARCALYST; average therapy duration ~20 months; 45% of patients restarted within 8 weeks.
KPL-404 Phase 2 rheumatoid arthritis data expected in 1H 2024; $15.0M milestone from Genentech vixarelimab agreement.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Kiniksa Pharmaceuticals International, plc reported quarter ended June 30, 2023 results: revenue $71.5 million, net income $15.0 million. Guidance raised.

Period: quarter ended June 30, 2023
Revenue: $71.5 million
Net income: $15.0 million
Guidance: raised
Result: reported results

Exact text from the filing

Financial Results • Total revenue for the second quarter of 2023 was $71.5 million, compared to $27.0 million for the second quarter of 2022. - Total revenue for the second quarter of 2023 included $54.5 million in ARCALYST net product revenue and $17.0 million in license and collaboration revenue, compared to $27.0 million in ARCALYST net product revenue and $0.0 million in license and collaboration revenue for the second quarter of 2022. • Total operating expenses for the second quarter of 2023 were $74.6 million, compared to $46.3 million for the second quarter of 2022. - Total operating expenses for the second quarter of 2023 included $6.5 million in non-cash, share-based compensation expense, compared to $6.7 million for the second quarter of 2022. • Net income for the second quarter of 2023 was $15.0 million, compared to a net loss of $20.0 million for the second quarter of 2022. - Net income for the second quarter of 2023 included a $16.2 million tax benefit primarily due to the

View on SEC.gov

Browse all earnings releases →

Kiniksa Pharmaceuticals International, plc filing history →

Source: SEC EDGAR

accession 0001104659-23-083629

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.